Girish Putcha

PowerVision, Inc. develops fluid-controlled intraocular lens. The firm provides FluidVision accommodating intraocular lens technology, which restores the vision of youth to middle aged or elderly individuals affected by presbyopia and cataracts regain to adjust focus for clear vision at all distances. The company was founded by Matthew A. Frinzi, Randy McDonald, and Barry Cheskin in 2002 and is headquartered in Belmont, CA.

Novasys Medical, Inc. develops therapies for women's health. The company was founded by Stuart D. Edwards and Peter S. Edelstein on June 24, 1999 and is headquartered in Newark, CA.

Phenomix Corp. is a biopharmaceutical company focused on the discovery, development and commercialization of novel small-molecule product candidates directed toward clinically validated targets in significant therapeutic markets. It's internally discovered product candidates are designed to have improved efficacy, safety or convenience relative to existing therapies and other product candidates in clinical development. Its lead product candidate, dutogliptin tartrate, is a dipeptidyl peptidase-4, or DPP-4, inhibitor that it is developing as an oral, once-daily treatment for Type 2 diabetes. Its Phase 2b clinical trial of dutogliptin demonstrated statistically significant reductions in HbA1c when administered in combination with existing drugs for the treatment of Type 2 diabetes. The company commenced its Phase 3 clinical program in the third quarter of 2008. Its second product candidate, PHX1766, is a protease inhibitor currently in Phase 1 of clinical development for the treatment of hepatitis C virus, or HCV, infection. The company intends to maximize the value of its product candidates through independent development, licensing and other partnership opportunities. These may include co-development or co-marketing agreements, licensing agreements with pharmaceutical and biotechnology companies that possess established development and commercialization capabilities or direct commercialization by building its own sales and marketing force.

Aviir, Inc. discovers, develops and commercializes diagnostic laboratory tests for cardiovascular diseases. The biotechnology company specializes in developing proprietary diagnostic tests to assist in identifying patients who are truly at high risk for the development of a cardiac event. The company was founded in 2005 and is headquartered in Irvine, CA.

CardioDx, Inc. operates as a cardiovascular genomic diagnostics firm. It develops proprietary tests that improve treatment decisions and patient outcomes on coronary artery disease, cardiac arrhythmia, and heart failure. The company was founded by David L. Levison and Christopher R. Burrow in 2004 and is headquartered in Redwood, CA.

Panorama Capital LLC (Panorama Capita) is a venture capital firm founded in 1995 by Chris Albinson, Rod Ferguson, Shahan Soghikian and damion wicker. The firm is headquartered in Campbell, California.

TOMA Biosciences, Inc. develops and provides DNA-based cancer testing technology. The company was founded by Hanlee Ji, Lincoln Nadauld, James M. Ford, and Calvin J. Kuo in 2011 and is headquartered in Foster City, CA.

Palmetto GBA LLC provides medical services. Its services include transaction processing, technological connectivity, professional education and training, and clinical decision management. The company was founded in July 1966 and is headquartered in Columbia, SC.